Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Fenfluramine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    $ API Ref.Price (USD/KG) : 97,339Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Results for UCB's Fintepla pave way for 3rd epileptic indication
    Results for UCB's Fintepla pave way for 3rd epileptic indication

    08 Dec 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/fast-rising-ucb-set-file-approval-fintepla-3rd-epileptic-disorder

    FIERCE PHARMA
    08 Dec 2025
    Share Share
    UCB Shares Leading Research at AES Annual Meeting
    UCB Shares Leading Research at AES Annual Meeting

    04 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ucb-shares-leading-scientific-research-and-advances-at-american-epilepsy-society-annual-meeting-302633101.html

    PR NEWSWIRE
    04 Dec 2025
    Share Share
    FINTEPLA (OLE) Study Results In Lennox-Gastaut Syndrome Published
    FINTEPLA (OLE) Study Results In Lennox-Gastaut Syndrome Published

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/final-analysis-of-open-label-extension-ole-study-of-fintepla-fenfluramine-in-lennox-gastaut-syndrome-published-in-epilepsy--behavior-302583331.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    UCB's Fintepla shows potential to treat a 3rd epilepsy disorder
    UCB's Fintepla shows potential to treat a 3rd epilepsy disorder

    28 Jun 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/ucbs-fintepla-shows-potential-expand-3rd-epilepsy-indication

    FIERCE PHARMA
    28 Jun 2025
    Share Share
    UCB Reports Positive Ph3 GEMZ Results in CDKL5 Disorder
    UCB Reports Positive Ph3 GEMZ Results in CDKL5 Disorder

    27 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ucb-announces-positive-results-from-gemz-phase-3-study-of-fenfluramine-in-cdkl5-deficiency-disorder-302492480.html

    PR NEWSWIRE
    27 Jun 2025
    Share Share
    Epilepsia Publishes FINTEPLA Long-Term Safety Data In Dravet
    Epilepsia Publishes FINTEPLA Long-Term Safety Data In Dravet

    12 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/epilepsia-publishes-final-analysis-of-open-label-extension-study-of-long-term-safety-and-effectiveness-of-fintepla-fenfluramine-in-children-and-adults-with-dravet-syndrome-302400217.html

    PR NEWSWIRE
    12 Mar 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.